Posted by: fuadelhibri on: August 19, 2010
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates Emergent reaffirms 2010 guidance for revenues and net income ROCKVILLE, Md., Aug 12, 2010 (BUSINESS [...]
Posted by: fuadelhibri on: July 13, 2010
ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) – Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation is composed of parliamentarians from Canada, Estonia, France, Finland, [...]
Posted by: fuadelhibri on: August 17, 2009
BioPort is the only FDA-licensed producer of the anthrax vaccine. Fuad El-Hibri, chairman and CEO of Emergent BioSolutions Inc., speaks March 9 in Sage Hall. Kevin Stearns/University Photography On March 9, MBA students taking International Political Risk Management, a course taught by Elena Iankova, a lecturer at the S.C. Johnson Graduate School of Management, heard [...]
Posted by: fuadelhibri on: August 17, 2009
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share. EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the [...]
Posted by: fuadelhibri on: August 17, 2009
On a business wire press release Emergent biosolutins reports :: ROCKVILLE, Md. – (Business Wire) Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, received the Ernst & Young Entrepreneur of the Year® 2009 Award in the Technology category in Greater Washington. According to Ernst & Young LLP, the [...]
Posted by: fuadelhibri on: August 17, 2009
Type: Public On the web: http://www.emergentbiosolutions.com Employees: 587 Employee growth: 4.8% Emergent BioSolutions protects your thorax against anthrax. Emergent BioSolutions develops and produces, for government and commercial markets, drugs that treat or protect against infectious diseases and bio-agents. The company supplies BioThrax (the US’s only FDA-approved anthrax vaccine) primarily to the departments of Defense and [...]
